Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

Overview

The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).

Full Title of Study: “A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: December 6, 2022

Interventions

  • Biological: Tezepelumab Dose 1
    • Subcutaneous injection.
  • Biological: Tezepelumab Dose 2
    • Subcutaneous injection.
  • Biological: Omalizumab
    • Subcutaneous injection.
  • Biological: Placebo
    • Subcutaneous injection.

Arms, Groups and Cohorts

  • Active Comparator: Group 1: Omalizumab
    • Participants naive to anti-IgE therapies will receive omalizumab.
  • Placebo Comparator: Group 2: Placebo
    • Participants naive to anti-IgE therapies will receive a placebo.
  • Experimental: Group 3: Tezepelumab Dose 1
    • Participants naive to anti-IgE therapies will receive tezepelumab.
  • Experimental: Group 4: Tezepelumab Dose 2
    • Participants naive to anti-IgE therapies will receive tezepelumab.
  • Placebo Comparator: Group 5: Placebo
    • Participants previously treated with anti-IgE therapies will receive a placebo.
  • Experimental: Group 6: Tezepelumab Dose 1
    • Participants previously treated with anti-IgE therapies will receive tezepelumab.
  • Experimental: Group 7: Tezepelumab Dose 2
    • Participants previously treated with anti-IgE therapies will receive tezepelumab.

Clinical Trial Outcome Measures

Primary Measures

  • Change from Baseline in Urticaria Activity Score over 7 days (UAS7)
    • Time Frame: Baseline to Week 16

Secondary Measures

  • Number of Participants with a Complete Response in Urticaria Activity Score over 7 Days (UAS7)
    • Time Frame: Week 16
    • Complete response is defined as having a UAS7 score of 0 at week 16.
  • Change from Baseline in Itch Severity Score over 7 Days (ISS7)
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Hives Severity Score over 7 Days (HSS7)
    • Time Frame: Baseline to Week 16
  • Number of Participants with a Urticaria Activity Score over 7 days (UAS7) Score of 6 or Below
    • Time Frame: Week 16
  • Number of Participants with a Change from Baseline in Urticaria Activity Score over 7 days (UAS7) of 10 or More
    • Time Frame: Baseline to Week 16
  • Number of Participants with a Complete Resolution of Itch using the Itch Severity Score over 7 Days (ISS7)
    • Time Frame: Week 16
    • Complete resolution of itch is defined as having a ISS7 score of 0 at week 16.
  • Number of Participants with a Change from Baseline in Itch Severity Score over 7 days (ISS7) of 5 or More
    • Time Frame: Baseline to Week 16
  • Number of Participants with a Complete Resolution of Hives using the Hives Severity Score over 7 Days (HSS7)
    • Time Frame: Week 16
    • Complete resolution of hives is defined as a HSS7 score of 0 at week 16.
  • Number of Participants with a Change from Baseline in Hives Severity Score over 7 Days (HSS7) of 5.5 or More
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Sleep Interference Score
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Sleep Quality Diary Items
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Urticaria Control Test (UCT) Score
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Angioedema Activity Score over 7 Days (AAS7)
    • Time Frame: Baseline to Week 16
  • Number of Cumulative Weeks that Participants are Angioedema Occurrence-free using the Angioedema Activity Score over 7 Days (AAS7)
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Dermatology Life Quality Index (DLQI) Score
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Angioedema Quality of Life Questionnaire (AE-QoL) Score
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Angioedema Control Test (AECT) Score
    • Time Frame: Baseline to Week 16
  • Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score
    • Time Frame: Baseline to Week 16
  • Total Number of H1-antihistamine Rescue Medication Uses
    • Time Frame: Baseline to Week 16
  • Maximum Observed Concentration of Tezepelumab in Serum (Cmax)
    • Time Frame: Baseline to Week 16
  • Number of Participants who Experience an Adverse Event (AE)
    • Time Frame: Baseline to Week 32
  • Number of Participants who Experience a Serious Adverse Event (SAE)
    • Time Frame: Baseline to Week 32

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent must be obtained prior to participation in the study. – Male and female participants ≥ 18 years and ≤ 80 years of age at the time of screening. – Chronic spontaneous urticaria (CSU) diagnosis for ≥ 6 months at the time of screening. – Diagnosis of CSU inadequately controlled by sgAH at enrollment, as defined by all of the following: – The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to screening visit 2 despite current use of an approve dose of H1-antihistamine. – UAS7 (range 0-42) ≥ 16 and HSS7 (range 0-21) ≥ 8 during the 7 days prior to enrollment. – Participant with CSU who discontinued, is intolerant to, or was an inadequate responder to anti-IgE therapies despite being treated with omalizumab 300 mg every 4 weeks (Q4W) for 6 months or higher doses of omalizumab > 2 months or another anti-IgE therapy. Note: This criterion is not applicable for anti-IgE-naïve participants. – Participant willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules. – Subject must have been on a sgAH at approved or increased doses (up to 4x the approved dose) for treatment of CSU for at least 3 consecutive days immediately prior to the day -14 screening visit (screening visit 2) and must have documented current use on the day of screening visit 1 Exclusion Criteria:

Disease related, including but not limited to:

  • Urticaria is solely due to inducible urticaria – Active dermatologic diseases (or conditions) other than chronic urticaria, with urticaria wheals or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to C1 inhibitor deficiency) – Any other active skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (eg, atopic dermatitis, dermatitis herpetiformis, senile pruritus, etc.) – History of a clinically significant infection within 28 days prior to day 1 that, in the opinion of the investigator or medical monitor, might compromise the safety of the participant in the study, interfere with evaluation of the investigational product, or reduce the participants ability to participate in the study. – Evidence of active tuberculosis (TB) (in the opinion of the investigator), either treated or untreated, or a positive purified protein derivative (PPD) or QuantiFERON-TB Gold Plus (QFT-Plus) test for TB during screening. – History of malignancy, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 12 months prior to screening or other malignancies treated with apparent success with curative therapy ≥ 5 years prior to screening visit 1. – Inability to complete an electronic participant diary or complete questionnaires, or does not meet the required level of compliance (≥ 80%) with the eDiary during the second phase of the screening period/H1-antihistamine stabilization period. Other medical conditions – History or evidence of severe depression, schizophrenia, previous suicide attempts, or suicidal ideation. Prior/concomitant therapy, including but not limited to: – Treatment with any anti-IgE therapies (eg, omalizumab, ligelizumab) within 6 months prior to screening visit 1. – Routine (daily or every other day for 5 or more consecutive days) use of systemic corticosteroids, systemic hydroxychloroquine, methotrexate, cyclosporine A, cyclophosphamide, tacrolimus, azathioprine, and mycophenolate mofetil within 30 days prior to screening visit 1. – Major surgery within 8 weeks prior to screening visit 1 or planned inpatient surgery or hospitalization during the study period. – Receipt of Ig or blood products within 30 days prior to screening visit 1. – Vaccination with a live or attenuated vaccine within 30 days prior to screening visit 1. Receipt of inactive/killed vaccinations (eg, inactive influenza) is allowed, provided the vaccinations are not administered within 7 days before or after any study visit. – Known hypersensitivity, including severe hypersensitivity reactions and/or history of anaphylactic shock, to any of the products or components to be administered during dosing or to products of similar chemical classes (ie, to murine, chimeric, or human antibodies.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Amgen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • MD, Study Director, Amgen
  • Overall Contact(s)
    • Amgen Call Center, 866-572-6436, medinfo@amgen.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.